• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of biosimilar investigational new drug applications (INDs) received in the month

Dictionary: Biosimilar investigational new drug application refers to an investigation that FDA determines is intended to support a biosimilar biological product application for a product.

Information is current as of March 31, 2015.

Fiscal Year - 2015

Skip graphic and jump to text data

Oct 2014N/A0
Nov 2014N/A0
Dec 2014N/A2
Jan 2015N/A1
Feb 2015N/A0
Mar 2015N/A0
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 3


  • CDER began collecting data for this measure in January 2013.


Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.